A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

Journal of Clinical Psychiatry

Volumn 63, Issue 6, 2002, Pages 516-523

  Hirsch, Steven R ^a   Kissling, Werner ^a   Bäuml, Josef ^a   Power, Aidan ^a   O'Connor, Rory ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; NEGATIVE SYNDROME; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0036085374     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0609     Document Type: Article

References (31)

1. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials
2. Negative symptoms in schizophrenia: Neurobiological modals and treatment response
3. Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents
4. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia
5. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
6. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
7. Positron emission tomographic analysis of central 5-HT2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent ziprasidone
8. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone
9. An exploratory, haloperidol-controlled, dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
10. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
11. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
12. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia
13. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
14. Global Assessment of Functioning Scale (GAF Scale)
15. A new depression scale designed to be sensitive to change
16. The Quality of Life Scale: An instrument for rating schizophrenic deficit syndrome
17. A rating scale for drug-induced akathisia
18. A rating scale for extrapyramidal side effects
19. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
20. Long-term treatment of chronic schizophrenia patients with risperidone
21. Long-term treatment of chronic schizophrenia with risperidone: An open-label, multicenter study of 386 patients
22. Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable, schizophrenia
23. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial
24. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
25. Antipsychotic-induced weight gain: A comprehensive research synthesis
26. Olanzapine: Weight gain and therapeutic efficacy
27. Novel antipsychotics: Comparison of weight gain liabilities
28. Body weight gain induced by antipsychotic drugs: Mechanisms and management